+++
title = "DMT"
description = "N,N-Dimethyltryptamin - 'Spirit Molecule', endogenni psychedelikum"
weight = 5
+++

# DMT - N,N-Dimethyltryptamin

**DMT** (N,N-Dimethyltryptamin) je mocny psychedelicky tryptamin znamy jako **"Spirit Molecule"** (Molekula ducha). Je to **endogenni sloucenina** - prirozene se vyskytuje v lidskem tele, rostlinach i zviratech. DMT je aktivni slozkou ayahuascy a poskytuje intenzivni, ale kratke psychedelicke zazitky.

---

## Chemicka struktura

### Zakladni parametry

| Vlastnost | Hodnota |
|-----------|---------|
| **Chemicky nazev** | N,N-Dimethyltryptamin |
| **Alternativni nazvy** | Dimitri, Spirit Molecule, Businessman's Trip |
| **Molekularni vzorec** | C12H16N2 |
| **Molekularni hmotnost** | 188,27 g/mol |
| **CAS cislo** | 61-50-7 |
| **IUPAC** | 2-(1H-indol-3-yl)-N,N-dimethylethanamine |
| **SMILES** | CN(C)CCc1c[nH]c2ccccc12 |
| **InChI Key** | DMULVCHRPCFFGV-UHFFFAOYSA-N |

### Strukturni rodina tryptaminu

| Sloucenina | Struktura | Aktivita | Potence (relativni) |
|------------|-----------|----------|---------------------|
| **DMT** | N,N-DMT | Primo aktivni | 1.0x |
| **5-MeO-DMT** | 5-methoxy-DMT | Silnejsi | 4-6x |
| [Psilocin](@/alkaloids/psilocin.md) | 4-HO-DMT | Primo aktivni | 0.8x |
| [Psilocybin](@/alkaloids/psilocybin.md) | 4-PO-DMT | Prodrug | 0.7x |
| **Bufotenin** | 5-HO-DMT | Slabsi | 0.3x |
| **DET** | N,N-Diethyltryptamin | Aktivni | 0.5x |
| **DPT** | N,N-Dipropyltryptamin | Aktivni | 0.6x |

### Srovnani se serotoninem

```
Serotonin (5-HT):    HO-[Indol]-CH2-CH2-NH2
                          ^5
DMT:                    [Indol]-CH2-CH2-N(CH3)2

Psilocin (4-HO-DMT): HO-[Indol]-CH2-CH2-N(CH3)2
                          ^4

5-MeO-DMT:          CH3O-[Indol]-CH2-CH2-N(CH3)2
                          ^5
```

### Stereochemie a konformace

DMT neobsahuje chiralni centrum, proto existuje pouze jako jedna prostorova forma. Molekula vsak muze zaujmat ruzne konformace:

- **Extended konformace** - dominantni v roztoku
- **Folded konformace** - preferovana pri vazbe na receptor
- **Planarna konformace** - indolovy kruh

---

## Fyzikalne-chemicke vlastnosti

| Vlastnost | Hodnota |
|-----------|---------|
| **Teplota tani** | 44,6-46,8 C |
| **Teplota varu** | 160 C (pri 0,6 mmHg) |
| **Barva** | Bila az nazloutla (krystaly) |
| **Zapach** | Charakteristicky (indolovy, "plastovy") |
| **Rozpustnost ve vode** | Spatna (volna baze) |
| **Rozpustnost v organickych rozpoustedlech** | Dobra |
| **pKa** | 8,68 |
| **Log P** | 1,54 (lipofilie) |
| **Vaporizacni teplota** | ~150-180 C |
| **Degradacni teplota** | >250 C |

### Stabilita

| Podminky | Stabilita |
|----------|-----------|
| **Svetlo** | Citlivy na UV |
| **Vzduch** | Oxidace pri dlouhodobe expozici |
| **Teplo** | Stabilni do 200 C |
| **pH** | Stabilni v neutralnim pH |
| **Skladovani** | Suche, tmave, chladne misto |

---

## Endogenni DMT

### Vyskyt v lidskem tele

DMT je **endogenni neurotransmiter** - prirozene se syntetizuje v lidskem organismu:

| Tkan/Tekutina | Pritomnost | Koncentrace | Reference |
|---------------|------------|-------------|-----------|
| **Mozek** | Potvrzeno | pg/g tkane | Barker 2018 |
| **Cerebrospinalni tekutina** | Potvrzeno | 0.1-5 ng/mL | Strassman 2001 |
| **Krev** | Stopy | <1 ng/mL | Karkkainen 2005 |
| **Moc** | Stopy | Variable | Barker 2012 |
| **Epifyza (sisinka)** | Spekulace | Nezmereno | Strassman hypoteza |
| **Plice** | Potvrzeno | INMT exprese | Thompson 2021 |
| **Ledviny** | Potvrzeno | INMT exprese | Dean 2019 |

### Detailni biosynteticka draha

```
L-Tryptofan (esencialni aminokyselina)
    |
    v [AADC - aromaticka L-aminokyselina dekarboxylaza]
    |   Kofaktor: pyridoxal-5'-fosfat (vitamin B6)
    |
Tryptamin
    |
    v [INMT - indolethylamin-N-methyltransferaza]
    |   Kofaktor: S-adenosylmethionin (SAM)
    |   Lokalizace: plice, mozek, ledviny
    |
N-Methyltryptamin (NMT)
    |
    v [INMT]
    |   Druha metylace
    |
N,N-Dimethyltryptamin (DMT)
```

### INMT - klicovy enzym

| Vlastnost | Hodnota |
|-----------|---------|
| **Gen** | INMT |
| **Lokalizace** | Chromozom 7p14.3 |
| **Exprese** | Plice > ledviny > mozek |
| **Regulace** | Stress, hypoxie |
| **Inhibitory** | Methionin, SAH |

### Teorie funkce endogenniho DMT

#### 1. Sigma-1 receptorovy agonista

DMT je potvrdenym agonistou [Sigma-1 receptoru](@/receptors/sigma-1.md):

| Funkce Sigma-1 | Dulezitost pro DMT |
|----------------|-------------------|
| **Chaperon aktivita** | Bunecna stresova odpoved |
| **Neuroprotekce** | Ochrana pred ischemii |
| **Imunomodulace** | Protizanetlive ucinky |
| **Regulace Ca2+ signalizace** | Neuroplasticita |

#### 2. Hypoteza NDE (Near-Death Experience)

```
Stresovy podnet (hypoxie, trauma)
    |
    v
Masivni INMT aktivace
    |
    v
Prudky narust endogenni DMT syntez
    |
    v
Zazitek blizke smrti (NDE)
    - Tunel svetla
    - Setkani s entitami
    - Zivotni flashback
    - Pocit transcendence
```

#### 3. REM spanek a sneni

| Hypoteza | Evidence |
|----------|----------|
| DMT uvolnovano behem REM | Neprime (zvysena INMT aktivita) |
| Souvislost s lucidnim snenim | Anekdoticka |
| Regulace spankoveho cyklu | Spekulativni |

#### 4. Perinatalni hypoteza

Rick Strassman teoretizoval, ze DMT muze byt uvolnovano:
- Pri porodu (novorozenec)
- Pri umrani
- Behem meditace

**Status**: Dosud nepotvrzeno primymi merenimi

---

## Pokrocila farmakologie

### Kompletni receptorovy profil

#### Primarne cile

| Receptor | Ki (nM) | Ucinek | Relevance |
|----------|---------|--------|-----------|
| [**5-HT2A**](@/receptors/5-ht2a.md) | 75-130 | Plny agonista | Hlavni psychoaktivni |
| [**5-HT2C**](@/receptors/5-ht2c.md) | 360 | Parcialni agonista | Modulace |
| [**Sigma-1**](@/receptors/sigma-1.md) | 14,750 | Agonista | Neuroprotekce |
| **TAAR1** | ~5,000 | Agonista | Modulace DA/5-HT |

#### Sekundarni cile

| Receptor | Ki (nM) | Ucinek |
|----------|---------|--------|
| **5-HT1A** | 1,000+ | Slaby agonista |
| **5-HT2B** | 2,000+ | Parcialni agonista |
| **5-HT6** | 4,000+ | Antagonista |
| **5-HT7** | 5,000+ | Slaby agonista |
| **D1** | >10,000 | Minimalni |
| **D2** | >10,000 | Minimalni |
| **Alpha-1** | 8,000 | Slaby agonista |
| **Alpha-2** | 12,000 | Slaby agonista |

### 5-HT2A signalni kaskada

```
DMT + 5-HT2A receptor
        |
        v
    Gq protein aktivace
        |
        +----------------+
        |                |
        v                v
    PLC-beta         beta-arrestin2
        |                |
        v                v
  IP3 + DAG         Internalizace
        |
    +---+---+
    |       |
    v       v
  [Ca2+]   PKC
    |       |
    v       v
NMDA     ERK1/2
modulace   |
           v
    Genova exprese
    (BDNF, Arc, Egr)
```

### Bias signalizace

DMT vykazuje **biased agonism** na 5-HT2A:

| Draha | Aktivace | Funkce |
|-------|----------|--------|
| **Gq/PLC** | Vysoka | Halucinace |
| **beta-arrestin** | Stredni | Desenzitizace |
| **Src kinazy** | Nizka | Plasticita |

### TAAR1 interakce

Trace amine-associated receptor 1:

| Aspekt | Hodnota |
|--------|---------|
| **Afinita DMT** | ~5,000 nM |
| **Funkce** | Modulace DA uvolnovani |
| **Lokalizace** | VTA, limbicky system |
| **Relevance** | Odmena, motivace |

### Sigma-1 mechanismus

```
DMT + Sigma-1 receptor (ER membrana)
        |
        v
Chaperon aktivace
        |
        +----------------+
        |                |
        v                v
   IP3R modulace    BiP disociace
        |                |
        v                v
   Ca2+ signaling   Stresova odpoved
        |                |
        v                v
  Neuroplasticita   Neuroprotekce
```

---

## Srovnavaci farmakokinetika

### Tabulka farmakokinetickych parametru

| Parametr | Inhalace | IM injekce | Ayahuasca | IV (Strassman) |
|----------|----------|------------|-----------|----------------|
| **Nastup** | 15-60 s | 2-5 min | 30-60 min | 30-60 s |
| **Tmax** | 2-5 min | 10-15 min | 90-120 min | 2 min |
| **Trvani** | 15-30 min | 30-60 min | 4-6 h | 20-30 min |
| **t1/2** | ~5 min | ~15 min | ~2 h | ~5 min |
| **Biologicka dostupnost** | ~100% | ~100% | ~50% | 100% |
| **Cmax** | Vysoka | Stredni | Nizsi, prolongovana | Velmi vysoka |
| **AUC** | Nizka | Stredni | Vysoka | Stredni |

### Metabolismus

#### Primarni metabolicke drahy

```
DMT
  |
  +--[MAO-A]-----> Indol-3-acetaldehyd (IAA)
  |                      |
  |                      v
  |               Indol-3-octova kyselina
  |
  +--[CYP2D6]----> DMT-N-oxid
  |
  +--[INMT reverzni]--> NMT --> Tryptamin
```

#### Enzymaticka kinetika MAO-A

| Parametr | Hodnota |
|----------|---------|
| **Km** | 13.7 uM |
| **Vmax** | 2.3 nmol/min/mg |
| **Katalyticka efektivita** | Vysoka |
| **Organova distribuce** | Jatra > mozek > GIT |

### Obejiti MAO degradace

Strategie pro oralni biodostupnost:

| Metoda | Mechanismus | Priklad |
|--------|-------------|---------|
| **Ireverzibilni MAOI** | Trvalá inhibice | Fenelzin (nezadouci) |
| **Reverzibilni MAOI-A** | Kompetitivni inhibice | Moclobemid |
| **Harmala alkaloidy** | Prirodni RIMA | Harmalin, harmin |
| **Sublingvalni** | Obejiti first-pass | DMT pod jazyk |

---

## Cesty podani

### 1. Vaporizace/Koureni

#### Technika

| Krok | Popis | Casovani |
|------|-------|----------|
| 1 | Priprava (pohodlna poloha, sitter) | Pred |
| 2 | Navazeni davky (15-50 mg) | Pred |
| 3 | Zahrati vaporizeru na 180 C | 0 s |
| 4 | Pomala, hluboka inhalace | 0-15 s |
| 5 | Zadrzeni dechu | 15-30 s |
| 6 | Opakovat 2-3x pro prulom | 30-90 s |
| 7 | Polozit se, zavrit oci | 90 s+ |

#### Davkovani

| Uroven | Davka | Zazitek |
|--------|-------|---------|
| **Prah** | 5-10 mg | Mirne vizualni zmeny |
| **Lehka** | 10-20 mg | Zretelne vizualy, otevrene oci |
| **Stredni** | 20-35 mg | Silne vizualy, zavrene oci |
| **Prulomova** | 35-50 mg | "Breakthrough", entity |
| **Silna** | 50-70 mg | Uplny prulom, ego smrt |

#### Vybaveni

| Typ | Vyhody | Nevyhody |
|-----|--------|----------|
| **GVG (Glass Vapor Genie)** | Efektivni, presne | Draha |
| **E-mesh** | Velmi efektivni | Technicka narocnost |
| **Dab rig** | Rychle | Spaleni mozne |
| **The Machine** | DIY, funkcni | Variabilni vysledky |

### 2. Ayahuasca (oralni + MAOI)

#### Tradicni priprava

**Slozky**:

| Rostlina | Funkce | Davka (sucha) |
|----------|--------|---------------|
| **Banisteriopsis caapi** | MAOI (harmin, harmalin) | 50-100 g |
| **Psychotria viridis** | DMT zdroj | 25-50 g |

**Priprava**:

```
1. Nakrajeni B. caapi na male kousky
2. Pridani P. viridis listu
3. Varime ve vode 4-12 hodin
4. Procedime, opakujeme 2-3x
5. Redukujeme na ~100-200 mL na davku
6. Skladujeme v chladnicce (max 1 tyden)
```

#### Alternativni kombinace

| DMT zdroj | MAOI zdroj | Region |
|-----------|------------|--------|
| P. viridis | B. caapi | Amazonie |
| M. hostilis | Peganum harmala | Modernni |
| A. confusa | B. caapi | Taiwan/Moderne |
| Phalaris | P. harmala | Experimentalni |

#### Cirkadiani timing

| Cas | Vhodnost | Duvod |
|-----|----------|-------|
| **Vecer (20:00-22:00)** | Idealni | Prirodni MAOI rytmus |
| **Pulnoc** | Tradicni | Samansky ritual |
| **Rano** | Mozne | Nizsi MAOI aktivita |

### 3. Pharmahuasca (synteticka ayahuasca)

| Varianta | DMT davka | MAOI | Poznamky |
|----------|-----------|------|----------|
| **Klasicka** | 30-50 mg | Harmalin 100-150 mg | Tradicni pomer |
| **Moclobemid** | 30-50 mg | Moclobemid 150 mg | Farmaceuticka |
| **Syrian rue** | 30-50 mg | P. harmala 3-4 g | Dostupna |

### 4. Intramuskulární (IM) injekce

| Aspekt | Hodnota |
|--------|---------|
| **Davka** | 0.5-1.0 mg/kg |
| **Nastup** | 2-5 minut |
| **Trvani** | 30-60 minut |
| **Vyhody** | Presne davkovani, hladky nastup |
| **Nevyhody** | Sterilita, technika |

### 5. Intravenzni (IV) - vyzkumne

Pouzivano v klinickych studiich (Strassman):

| Davka | Ucinek |
|-------|--------|
| 0.05 mg/kg | Prah |
| 0.1 mg/kg | Mirny |
| 0.2 mg/kg | Stredni |
| 0.4 mg/kg | Silny |

---

## Prirodni zdroje DMT

### Rostliny s vysokym obsahem DMT

#### Psychotria viridis (Chacruna)

| Vlastnost | Hodnota |
|-----------|---------|
| **Celed** | Rubiaceae |
| **Oblast** | Amazonie |
| **Pouzivana cast** | Listy |
| **Obsah DMT** | 0.1-0.61% |
| **Dalsi alkaloidy** | NMT (stopy) |
| **Tradicni pouziti** | Ayahuasca |

#### Mimosa hostilis (Jurema)

| Vlastnost | Hodnota |
|-----------|---------|
| **Celed** | Fabaceae |
| **Oblast** | Severovchdni Brazilie |
| **Pouzivana cast** | Kura korene |
| **Obsah DMT** | 0.31-1.7% |
| **Dalsi alkaloidy** | NMT, 5-MeO-DMT (stopy) |
| **Tradicni pouziti** | Jurema ritual |

#### Acacia confusa

| Vlastnost | Hodnota |
|-----------|---------|
| **Celed** | Fabaceae |
| **Oblast** | Jihovychodni Asie, Taiwan |
| **Pouzivana cast** | Kura korene |
| **Obsah DMT** | 0.2-1.5% |
| **Dalsi alkaloidy** | NMT |
| **Poznamka** | Popularnni extrakce |

#### Anadenanthera peregrina (Yopo)

| Vlastnost | Hodnota |
|-----------|---------|
| **Celed** | Fabaceae |
| **Oblast** | Jizni Amerika |
| **Pouzivana cast** | Semena |
| **Obsah DMT** | 0.1-0.5% |
| **Dalsi alkaloidy** | 5-MeO-DMT, bufotenin |
| **Pouziti** | Snupaci prasek |

### Tabulka prirodnich zdroju

| Rostlina | Cast | DMT % | NMT % | 5-MeO-DMT % | Region |
|----------|------|-------|-------|-------------|--------|
| P. viridis | Listy | 0.1-0.6 | Stopy | - | Amazonie |
| M. hostilis | Kura | 0.3-1.7 | 0.1 | Stopy | Brazilie |
| A. confusa | Kura | 0.2-1.5 | 0.1 | - | Asie |
| A. peregrina | Semena | 0.1-0.5 | - | 0.1-0.3 | J. Amerika |
| Phalaris arundinacea | Trava | 0.01-0.1 | - | 0.01 | Globalni |
| Desmanthus illinoensis | Koren | 0.2-0.3 | - | - | S. Amerika |
| Virola spp. | Kura | 0.1-0.5 | - | Ano | Amazonie |

### Zvirecti zdroje

| Zivocich | Sloucenina | Poznamka |
|----------|------------|----------|
| **Bufo alvarius** | 5-MeO-DMT | Kozni sekrece |
| Clovek | DMT | Endogenni |
| Krysy | DMT | Endogenni (vyzkum) |

---

## Neurobiologie DMT zazitku

### Default Mode Network (DMN)

DMT vyrazne ovlivnuje Default Mode Network:

| DMN struktura | Zmena | Dulezitost |
|---------------|-------|------------|
| **Medialni prefrontalni kortex** | Pokles aktivity | Ego |
| **Posteriorrni cingularni kortex** | Pokles aktivity | Sebereferrence |
| **Lateralni temporalni kortex** | Pokles aktivity | Sebnarativ |
| **Angularni gyrus** | Pokles aktivity | Telenost |

```
Normalni stav:           DMT stav:
DMN vysoka aktivita      DMN nizka aktivita
    |                        |
    v                        v
Pevne ego               Ego disoluce
Stabilni self           Oceanicka jednota
Predvidatelnost         Entropie/kreativita
```

### Vizualni kortex

| Oblast | Zmena | Fenomen |
|--------|-------|---------|
| **V1 (primarni)** | Hyperaktivace | Zakladni geometrie |
| **V2** | Hyperaktivace | Komplexni vzory |
| **V4** | Hyperaktivace | Barvy, formy |
| **IT kortex** | Hyperaktivace | Entity, obrazky |
| **MT/V5** | Hyperaktivace | Pohyb vzoru |

### Entropic Brain Hypothesis

```
Kontrola energie:    Kritikalita:     Entropy:
Nizka               Optimaln          Vysoka
    |                   |                |
    v                   v                v
Rigidita           Flexibilita     Chaos
(Deprese)          (Zdrave)        (Psychoza)

DMT posunuje smerem k vyssi entropii (kontrolovane)
```

### Claustrum a vedomi

DMT ovlivnuje claustrum - moznou strukturu pro integraci vedomi:

| Aspekt | Normalni | Pod DMT |
|--------|----------|---------|
| **Aktivita** | Koordinovana | Diskoordinovana |
| **Synchronizace** | Vysoka | Nizka |
| **Subjektivni efekt** | Jednotne vedomi | Fragmentace/expanze |

### Gamma oscilace

| Parametr | Baseline | Pod DMT | Vyznam |
|----------|----------|---------|--------|
| **Gamma frekvence** | 30-100 Hz | Zvysena | Percepce |
| **Theta aktivita** | 4-8 Hz | Zvysena | Pametove zpracovani |
| **Alpha aktivita** | 8-12 Hz | Snizena | Relaxace |

---

## Fenomenologie DMT zazitku

### Faze zazitku

#### Faze 1: Nastup (0-30 sekund)

| Fenomen | Popis |
|---------|-------|
| **Telesne bzuceni** | Vibrace prostupujici telem |
| **Auditory zmeny** | Zvoneni, bzuceni, "carrier wave" |
| **Vizualni onset** | Zesvtleni, barevne posuny |
| **Telesne rozpousteni** | Pocit ztraceni hranic tela |

#### Faze 2: Chrysanthemum (30-60 sekund)

| Fenomen | Popis |
|---------|-------|
| **Geometricke vzory** | Fraktalni, kaleidoskopicke |
| **"Chrysanthemum" vzorek** | Specificky mandala-like vzor |
| **Tunel** | Pocit pohybu "vpred" |
| **Barvy** | Hypersaturovane, neonove |

#### Faze 3: Prulom (1-5 minut)

| Fenomen | Popis |
|---------|-------|
| **"Breaking through"** | Proniknuti "za" realitu |
| **Jine dimenze** | Zazitky jinych svetov |
| **Entity** | Setkani s bytostmi |
| **Hyperrealita** | Vice realne nez realita |

#### Faze 4: Navrat (5-15 minut)

| Fenomen | Popis |
|---------|-------|
| **Postupne vynorovani** | Navrat do tela |
| **Rezidualni vizualy** | Doznivajici obrazce |
| **Emocionalni processing** | Zpracovani zazitku |
| **Reintegrace** | Znovuziskani ega |

### DMT entity - detailni analyza

#### Typologie entit

| Typ | Popis | Frekvence |
|-----|-------|-----------|
| **Machine Elves** | Male, hyperaktivni, zarte bytosti | 25% |
| **Jesters/Tricksters** | Ssskovske, hrave entity | 15% |
| **Mantis beings** | Hmyzi, "lekarske" bytosti | 10% |
| **Humanoidni** | Lidske rysy, casto "feminine" | 20% |
| **Geometricke** | Abstraktni, matematicke formy | 15% |
| **Amorfni** | Neursite, menisci se entity | 15% |

#### Fenomenologie setkani

| Aspekt | Popis |
|--------|-------|
| **Autonomie** | Entity se zdaji byt nezavisle |
| **Inteligence** | Projevuji cilevdome chovani |
| **Komunikace** | Casto "telepaticka" |
| **Emoce** | Prekvapeni nad navstevnikem |
| **Uceni** | Snaha neco "ukazat" ci "predat" |

#### McKennovy "Self-Transforming Machine Elves"

Terence McKenna detailne popsal typicke setkani:

> *"Entity vas ocekavaji. Jsou nadenceni, ze jste dorazili. Predhazuji vam objekty - samopretvrajici se stroje jazykove podstaty, ktere jsou zaroven hracky, nastroje a umelecka dila."*

#### Interpretacni ramce

| Interpretace | Popis | Zastanci |
|--------------|-------|----------|
| **Neurologicka** | Projekce mozkove aktivity | Vedecky mainstream |
| **Psychoanalyticka** | Archetypy nevedomi | Jung, Grof |
| **Ontologicka** | Skutecne bytosti | McKenna, nekteri filozofove |
| **Informacni** | Pristup k "datovemu poli" | Sheldrake |

### Mysticke zazitky

DMT konzistentne indukuje mysticke zazitky merene MEQ (Mystical Experience Questionnaire):

| Dimenze MEQ | Skore (DMT) | Skore (psilocybin) |
|-------------|-------------|-------------------|
| **Jednota** | 85% | 75% |
| **Transcendence casu/prostoru** | 90% | 70% |
| **Posvstnost** | 70% | 65% |
| **Noeticky insight** | 80% | 70% |
| **Pozitivni nalada** | 75% | 80% |
| **Nevyslovitelnost** | 95% | 85% |

---

## Historie vyzkumu

### Predvedecka era

| Rok | Udalost |
|-----|---------|
| **~prehistorie** | Tradicni pouziti ayahuascy |
| **1500s** | Evropske zpravy o "carovnych napojich" |
| **1851** | Spruce dokumentuje ayahuascu |
| **1923** | Fischer izoluje harmin |

### Vedecke objevy

| Rok | Udalost | Vyznam |
|-----|---------|--------|
| **1931** | Manske syntetizuje DMT | Prvni synteza |
| **1955** | Szara objevuje psychoaktivitu | Prvni lidske studie |
| **1956** | Szara IM studie | Systematicky vyzkum |
| **1965** | Franzen & Gross - endogenni DMT | Klicovy objev |
| **1972** | Saavedra & Axelrod - INMT | Biosynteticky enzym |

### Strassmanovy studie (1990-1995)

Prulomovy vyzkum Dr. Ricka Strassmana na University of New Mexico:

#### Metodologie

| Parametr | Hodnota |
|----------|---------|
| **Ucastnici** | 60 dobrovolniku |
| **Davky** | 0.05-0.4 mg/kg IV |
| **Celkem sezeni** | 400+ |
| **Mereni** | Fyziologicke + subjektivni |
| **FDA schvaleni** | Ano (prulomove) |

#### Klicove nalezy

| Nalez | Detail |
|-------|--------|
| **Reprodukovatelnost** | Podobne zazitky u ruznych subjektu |
| **Davkova zavislost** | Vyssi davka = intenzivnejsi zazitek |
| **Entity** | ~50% reportovalo setkani s bytostmi |
| **Bezpecnost** | Zadne zavazne nezadouci ucinky |
| **Tolerance** | Minimalni/zadna kractkodobe |

#### Fyziologicke zmeny

| Parametr | Zmena | Peak |
|----------|-------|------|
| **Krevni tlak (systolicky)** | +25 mmHg | 2 min |
| **Krevni tlak (diastolicky)** | +15 mmHg | 2 min |
| **Srdecni frekvence** | +15 bpm | 2 min |
| **Telesna teplota** | +0.5 C | 5 min |
| **Kortizol** | +100% | 30 min |
| **Prolaktin** | +50% | 30 min |
| **beta-endorfin** | +100% | 15 min |
| **Rustovy hormon** | +300% | 30 min |

### Moderni renesance (2000-present)

| Rok | Instituce | Studie |
|-----|-----------|--------|
| **2012** | Imperial College | fMRI ayahuasca |
| **2015** | Imperial College | EEG DMT |
| **2019** | Imperial College | Extended-state DMT |
| **2020** | Centre for Psychedelic Research | DMT a NDE |
| **2021** | Johns Hopkins | DMT entity survey |
| **2023** | Small Pharma | DMTx deprese Phase II |

---

## Terapeuticky potencial

### Deprese

#### Mechanismy

| Mechanismus | Evidence |
|-------------|----------|
| **5-HT2A agonismus** | Antikomformni efekty |
| **Neuroplasticita** | BDNF indukce |
| **Default Mode Network reset** | Ruminativni mysleni |
| **Mysticka zkusenost** | Korealce s trvalymi zmenami |

#### Klinicke studie

| Studie | N | Vysledek |
|--------|---|----------|
| **Osorio 2015** (ayahuasca) | 6 | Vyznamne zlepseni |
| **Palhano-Fontes 2019** | 29 | Rychla antidepresivni odpoved |
| **Small Pharma 2023** | 34 | Faze II pozitivni |

### PTSD

| Mechanismus | Relevance |
|-------------|-----------|
| **Fear extinction** | Enhanced memory reconsolidation |
| **Emotional processing** | Trauma reprocessing |
| **Neuroplasticita** | Nove neuronalni spoje |

### Zavislosti

| Substance | Studie | Vysledek |
|-----------|--------|----------|
| **Alkohol** | Ayahuasca observacni | Snizeni craving |
| **Kokain** | Ayahuasca observacni | Remise |
| **Tabak** | Ayahuasca observacni | Abstinence |

### Existencialni distress

| Indikace | Potencial |
|----------|-----------|
| **Terminalni onemocneni** | Snizeni anxiety |
| **Strach ze smrti** | Transformativni insight |
| **Existencialni krize** | Novy smysl |

### DMTx - prodlouzeny stav

Imperial College vyviji "DMTx" protokol:

| Aspekt | Popis |
|--------|-------|
| **Koncept** | Kontinualni IV DMT infuze |
| **Trvani** | 30-60 minut (vs 15 min) |
| **Vyhoda** | Delsi terapeuticke okno |
| **Status** | Faze I dokoncena |

---

## 5-MeO-DMT - srovnani

### Farmakologicke rozdily

| Parametr | DMT | 5-MeO-DMT |
|----------|-----|-----------|
| **5-HT2A Ki** | 75-130 nM | 3-10 nM |
| **5-HT1A Ki** | 1000+ nM | 5-30 nM |
| **Potence** | 1x | 4-6x |
| **Metabolismus** | MAO-A, CYP2D6 | MAO-A |

### Fenomenologicke rozdily

| Aspekt | DMT | 5-MeO-DMT |
|--------|-----|-----------|
| **Vizualni** | Velmi silne | Minimalni/zadne |
| **Entity** | Caste | Vzacne |
| **Ego smrt** | Mozna | Temer jista |
| **Telesne** | Stredni | Intenzivni |
| **Charakter** | "Vizionarsky" | "Sjednocujici" |
| **Srovnani** | Kaleidoskop | Bily plamen |

---

## Bezpecnost a rizika

### Fyziologicka bezpecnost

| Aspekt | Hodnoceni |
|--------|-----------|
| **LD50** | >50 mg/kg (velmi nizka toxicita) |
| **Kardiotoxicita** | Minimalni (kratkodobe zvyseni TK) |
| **Neurotoxicita** | Neprukazana |
| **Hepatotoxicita** | Neprukazana |
| **Zavislostni potencial** | Velmi nizky |
| **Tolerance** | Minimalni |

### Psychologicka rizika

| Riziko | Pravdepodobnost | Prevence |
|--------|-----------------|----------|
| **Uzkost/panika** | 10-20% | Set & setting |
| **Traumaticky zazitek** | 5-10% | Sitter, integrace |
| **HPPD** | <1% | Vyhybat se u predisponovanych |
| **Prolongovana psychoza** | Velmi vzacne | Kontraindikace |

### Kontraindikace

#### Absolutni

- Schizofrenie nebo psychoza v anamneze
- Aktualni psychoticka epizoda
- Bipolarni porucha I. typu
- Tezka kardiovaskularni choroba

#### Relativni

- Uzkostne poruchy
- Deprese s psychotickymi rysy
- SSRI/SNRI (serotonin syndrom s MAOI)
- Gravidita

### Interakce

| Latka | Typ interakce | Zavaznost |
|-------|---------------|-----------|
| **MAOI (lekove)** | Potenciace | Vysoka |
| **SSRI** | Serotonin syndrom (s MAOI) | Vysoka |
| **Lithium** | Zvysene riziko zachvatu | Vysoka |
| **Tramadol** | Serotonin syndrom | Stredni |
| **Stimulanty** | Kardiovaskularni | Stredni |

---

## Pravni status

### Mezinarodni

| Jurisdikce | Status | Poznamka |
|------------|--------|----------|
| **OSN** | Schedule I (1971) | Umluva o psychotropnich latkach |
| **USA** | Schedule I | Vyjimky pro nektere cirkve |
| **EU** | Vetsinou zakazano | Variabilni implementace |
| **Brazilie** | Ayahuasca legalni | Nabozensky kontext |
| **Peru** | Ayahuasca legalni | Tradicni pouziti |
| **Portugalsko** | Dekriminalizovano | Osobni spotreba |

### Ceska republika

| Aspekt | Detail |
|--------|--------|
| **Zakon** | Narizeni vlady c. 463/2013 Sb. |
| **Kategorie** | Tabulka c. 1 - zakazane latky |
| **DMT** | Explicitne uvedeno |
| **Ayahuasca** | Pravne neursite |
| **Rostliny** | Obecne legalni (sedy zona) |

### Nabozenske vyjimky

| Cirkev | Zeme | Pravni zaklad |
|--------|------|---------------|
| **Santo Daime** | Brazilie, Nizozemsko, Spanelsko | Nabozenská svoboda |
| **Uniao do Vegetal** | USA, Brazilie | Soudni rozhodnuti (O Centro) |
| **Native American Church** | USA | AIRFA 1978 (peyotl) |

---

## Reference

### Primárni literatura

1. Strassman, R.J. (2001). *DMT: The Spirit Molecule*. Park Street Press.
2. McKenna, T. (1991). *The Archaic Revival*. HarperCollins.
3. Shulgin, A. & Shulgin, A. (1997). *TiHKAL*. Transform Press.
4. Barker, S.A. (2018). *N,N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen*. International Review of Neurobiology, 142, 77-121.
5. Carbonaro, T.M. & Gatch, M.B. (2016). *Neuropharmacology of N,N-Dimethyltryptamine*. Brain Research Bulletin, 126, 74-88.

### Klinicke studie

6. Strassman, R.J. et al. (1994). *Dose-response study of N,N-dimethyltryptamine in humans*. Archives of General Psychiatry, 51(2), 85-97.
7. Palhano-Fontes, F. et al. (2019). *Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression*. Psychological Medicine, 49(4), 655-663.
8. Timmermann, C. et al. (2018). *DMT Models the Near-Death Experience*. Frontiers in Psychology, 9, 1424.

### Neuroimaging

9. Carhart-Harris, R.L. et al. (2012). *Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin*. PNAS, 109(6), 2138-2143.
10. Timmermann, C. et al. (2019). *Neural correlates of the DMT experience assessed with multivariate EEG*. Scientific Reports, 9, 16324.

### Endogenni DMT

11. Dean, J.G. et al. (2019). *Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain*. Scientific Reports, 9, 9333.
12. Barker, S.A. et al. (2012). *A critical review of reports of endogenous psychedelic N,N-dimethyltryptamines in humans*. Drug Testing and Analysis, 4(7-8), 617-635.

### Entity fenomen

13. Davis, A.K. et al. (2020). *Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine*. Journal of Psychopharmacology, 34(9), 1008-1020.
14. Luke, D. (2011). *Discarnate entities and dimethyltryptamine (DMT)*. Journal of the Society for Psychical Research, 75(902), 26-42.

### Terapeuticky potencial

15. Osorio, F.L. et al. (2015). *Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression*. Journal of Clinical Psychopharmacology, 35(2), 150-158.
16. Sanches, R.F. et al. (2016). *Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression*. Journal of Clinical Psychopharmacology, 36(1), 77-81.

---

## Detailni mechanismy ucinku

Pro hlubsi studium viz [Mechanismy ucinku](@/mechanisms/_index.md):

### Dualni receptorovy mechanismus DMT

DMT je unikatni svou aktivitou na dvou odlisnych receptorovych systemech:

```
DMT DUALNI MECHANISMUS
======================

DRAHA 1: 5-HT2A (PSYCHEDELICKA)         DRAHA 2: SIGMA-1 (NEUROPROTEKTIVNI)
Ki = 75-130 nM                           Ki = 14,750 nM
|                                        |
v                                        v
Gq/11 -> PLCbeta                         Chaperon aktivace na ER
|                                        |
v                                        v
IP3/DAG -> Ca2+ -> PKC                   IP3R modulace, BiP disociace
|                                        |
v                                        v
ERK1/2 -> CREB -> BDNF                  Ca2+ homeostaze, stresova odpoved
|                                        |
v                                        v
HALUCINACE, NEUROPLASTICITA             NEUROPROTEKCE, IMUNOMODULACE
```

| Parametr | 5-HT2A draha | Sigma-1 draha |
|----------|-------------|---------------|
| **Afinita** | Vysoka (75-130 nM) | Nizka (14,750 nM) |
| **Casovy onset** | Sekundy | Minuty-hodiny |
| **Hlavni efekt** | Psychedelicky zazitek | Bunecna protekce |
| **Terapeuticky potencial** | Deprese, PTSD | Ischemia, neurodegenerace |
| **Endogenni relevance** | Stresova odpoved | Tonicka neuroprotekce |

Podrobnosti: [Receptorova kinetika](@/mechanisms/receptor-binding.md) | [Signalni transdukce](@/mechanisms/signal-transduction.md)

### MAO-zavislá farmakokinetika

DMT ma **unikatni PK profil** definovany MAO-A metabolismem:

```
BEZ MAOI (inhalacne/IV):     S MAOI (ayahuasca):
Tmax = 2-5 min               Tmax = 90-120 min
T1/2 = ~5 min                T1/2 = ~2 h
Trvani = 15-30 min           Trvani = 4-6 h

MAO-A Km = 13.7 uM
MAO-A Vmax = 2.3 nmol/min/mg

DMT bez MAOI:                DMT + harmin (MAOI):
    ^                             ^
    |/\                           |    ___
    |  \                          |   /   \
    |   \                         |  /     \
    |    \_                       | /       \___
    +-------->                    +------------>
    0  15  30 min                 0   2   4   6 h
```

Podrobnosti: [PK-PD vztahy](@/mechanisms/pharmacokinetic-pharmacodynamic.md)

---

## Krizove odkazy

### Souvisejici alkaloidy
- [Psilocybin](@/alkaloids/psilocybin.md) - 4-fosforolovany analog
- [Psilocin](@/alkaloids/psilocin.md) - 4-hydroxylovany analog
- [Baeocystin](@/alkaloids/baeocystin.md) - demetylovany psilocybin
- [Bufotenin](@/alkaloids/bufotenin.md) - 5-hydroxy-DMT

### Receptory
- [5-HT2A](@/receptors/5-ht2a.md) - primarni psychedelicky cil
- [5-HT2C](@/receptors/5-ht2c.md) - modulacni receptor
- [Sigma-1](@/receptors/sigma-1.md) - neuroprotektivni funkce
- [TAAR1](@/receptors/taar1.md) - trace amine receptor

### Mechanismy
- [Mechanismy ucinku](@/mechanisms/_index.md) - prehled mechanismu
- [Receptorova kinetika](@/mechanisms/receptor-binding.md) - vazebna kinetika
- [Signalni transdukce](@/mechanisms/signal-transduction.md) - 5-HT2A a Sigma-1 drahy
- [PK-PD vztahy](@/mechanisms/pharmacokinetic-pharmacodynamic.md) - MAO-zavisla farmakokinetika

### Farmakologie a metabolismus
- [MAOI](@/pharmacology/maoi.md) - inhibitory monoaminoxidazy, klic k oralni aktivite
- [First-pass metabolismus](@/pharmacology/first-pass-metabolism.md) - proc DMT neni oralne aktivni bez MAOI
- [Membranová permeabilita](@/pharmacology/membrane-permeability.md) - prostup hematoencefalickou bariérou
- [Farmakokinetika](@/pharmacology/_index.md) - absorpce, distribuce, eliminace

### Neuroveda a mechanismy
- [Neuroplasticita](@/glossary/neuroplasticita.md) - dlouhodobé změny po DMT expozici
- [BDNF](@/molecules/bdnf.md) - růstový faktor indukovaný DMT
- [Default Mode Network](@/circuits/dmn.md) - síť potlačená psychedeliky
- [Signální transdukce](@/mechanisms/signal-transduction.md) - 5-HT2A a Sigma-1 dráhy

### Přípravky a aplikace
- [Ayahuasca](@/preparations/ayahuasca.md) - tradiční MAOI-obsahující připravek
- **Changa** - kuřitelná DMT-MAOI směs
- **Pharmahuasca** - syntetická ayahuasca

### Fenomenologie a zkusenost
- [Mystické zážitky](@/phenomenology/mystical-experiences.md) - fenomenologie DMT breakthrough
- [Set and Setting](@/glossary/set-and-setting.md) - faktory ovlivňující zážitek
- **Entity encounters** - setkání s bytostmi

---

Zpet na [Alkaloidy](@/alkaloids/_index.md) | [Psilocybin](@/alkaloids/psilocybin.md) | [Muscimol](@/alkaloids/muscimol.md)
